glp 1 drug zepbound As Insurers Struggle With GLP-1 Costs, Some Seek To Wean Patients Off Lilly releases Zepbound (tirzepatide) single-dose

Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes

Am J Physiol (1996) 271(4 Pt 2):R84856

The Future of Incretin-Based Therapy Understanding GLP-1 versus GIP provides context for where this field is heading

In crude analyses, the use of GLP-1 receptor agonists generated an elevated hazard ratio compared with the use of DPP-4 inhibitors (crude hazard ratio 2.08, 95% confidence interval (CI) 1.83 to 2.36)

Because of this problem, drug companies are investing in better ways to help people lose weight

When an Integrative Approach Makes Sense There are situations where GLP-1 medications are medically necessary, particularly in advanced type 2 diabetes or severe metabolic disease